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Background: Sepsis is a common syndrome in critically ill patients and easily leads to the occurrence of acute
kidney injury (AKI), with high mortality rates. This study aimed to investigate the diagnostic value of urine soluble
CD163 (sCD163) for identification of sepsis, severity of sepsis, and for secondary AKI, and to assess the patients’
prognosis.
Methods: We enrolled 20 cases with systemic inflammatory response syndrome (SIRS), 40 cases with sepsis (further
divided into 17 sepsis cases and 23 severe sepsis cases) admitted to the intensive care unit (ICU), and 20 control
cases. Results for urine sCD163 were recorded on the day of admission to the ICU, and AKI occurrence was noted.
Results: On the day of ICU admission, the sepsis group exhibited higher levels of urine sCD163 (74.8 ng/ml; range:
47.9-148.3 ng/ml) compared with those in the SIRS group (31.9 ng/ml; 16.8-48.0, P < 0.001). The area under the
curve (AUC) was 0.83 (95% confidence interval [CI]: 0.72-0.94, P < 0.001) the sensitivity was 0.83, and the specificity
was 0.75 (based on a cut-off point of 43.0 ng/ml). Moreover, the severe sepsis group appeared to have a higher
level of sCD163 compared with that in the sepsis group (76.2; 47.2-167.5 ng/ml vs. 74.2; 46.2-131.6 ng/ml), but this
was not significant. For 15 patients with AKI, urine sCD163 levels at AKI diagnosis were significantly higher than
those of the remaining 35 sepsis patients upon ICU admission (121.0; 74.6-299.1 ng/ml vs. 61.8; 42.8-128.3 ng/ml,
P = 0.049). The AUC for urine sCD163 was 0.688 (95% CI: 0.51-0.87, P = 0.049). Sepsis patients with a poor prognosis
showed a higher urine sCD163 level at ICU admission (98.6; 50.3-275.6 ng/ml vs. 68.0; 44.8-114.5 ng/ml), but this
was not significant. Patients with AKI with a poor prognosis had higher sCD163 levels than those in patients with a
better prognosis (205.9; 38.6-766.0 ng/ml vs. 80.9; 74.9-141.0 ng/ml), but this was not significant.
Conclusions: This study shows, for the first time, the potential value of urine sCD163 levels for identifying sepsis
and diagnosing AKI, as well as for assessment of patients’ prognosis.
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Sepsis is one of the major factors affecting the incidence
of admission to the intensive care unit (ICU) and mortality
in the ICU [1]. Sepsis, which rapidly progresses, is likely to
be followed by secondary multi-organ dysfunction and
endangers the patient’s life. The kidney is most susceptible
to multiple organ failure. Therefore, the occurrence of
acute kidney failure injury (AKI) lengthens hospital stay,
decreases the inpatient’s budget, and increases mortality.
From a clinical point of view, it is imperative to discover
markers for early sepsis and AKI diagnosis, as well as for
the patients’ prognosis, to determine an earlier interven-
tion to save lives.
CD163 is a trans-membrane molecule, which has only
been discovered on the membrane of mononuclear-pha-
gocytes. CD163 is a specific scavenger receptor for
hemoglobin/heme in the body, capable of specific recogni-
tion of the hemoglobin-haptoglobin complex. Studies in
recent years have found that CD163 regulates the expres-
sion of anti-inflammatory molecules, such as interleukin-
10 and heme oxygenase-1 [2,3]. Soluble CD163 (sCD163)
comes from CD163 molecules, which peel off the mem-
brane of mononuclear cells [2,4]. It has been reported that
oxidative stress induced by H2O2 or a nitric oxide donor,
as well as 8-iso-prostaglandin F2α, induce significant shed-
ding of CD163 [5]. Feng et al [6] recently demonstrated
that sCD163 is a sepsis diagnostic biomarker and can dif-
ferentiate the severity of sepsis and the assessment of
prognosis. Some studies have also reported high serum
sCD163 expression in bacteremia patients and its value in
prognosis [7,8], as well as high serum sCD163 expression
in people with chronic kidney diseases [9]. CD163-Hb
scavenger receptors play an important role in the process
of clearance and conversion of hemoglobin/heme in
chronic kidney disease [10]. Currently, it is still unknown
whether sCD163 can be detected in urine and what value
it possesses for sepsis and AKI.
Therefore, the present study investigated whether there
are high sCD163 levels in urine with the occurrence of
sepsis and AKI, as well as its clinical significance.
Methods
All subjects were selected from inpatients hospitalized
between May 2010 and September 2011 in the Respira-
tory Intensive Care Unit (RIUC), Surgical Intensive Care
Unit (SIUC), and Emergency Intensive Care Unit (EICU)
of the Chinese People’s Liberation Army (PLA) General
Hospital. We obtained approval for the study from the
Ethics Committee of the Chinese PLA General Hospital
(project no. 20090923-001) and registered the study at
the China Clinical Trials Register (ChiCTR-ONC-
10000812). The subjects and their families were well
informed of the details and signed relevant contracts
prior to the study.Inclusion and exclusion criteria
In accordance with the 1991 ACCP/SCCM Sepsis Direc-
tory [11] and the diagnosis criteria advanced by the 2001
International Sepsis Definition Conference [12], systemic
inflammatory response syndrome (SIRS) was diagnosed
according to the following criteria: (1) temperature >38°C
or <36°C; (2) pulse rate >90 beats/min; (3) ventilatory rate
>20 breaths/min or hyperventilation with partial pressure
of arterial carbon dioxide (PaCO2) <32mmHg; and (4)
white blood cell count >12,000μL-1 or <4000μL-1, or >10%
immature cells. Sepsis is a systemic inflammatory response
to infection. Severe sepsis is defined as sepsis associated
with organ dysfunction, hypoperfusion abnormalities, or
sepsis-induced hypotension. When perfusion abnormalities
cannot be corrected by adequate fluid resuscitation, septic
shock occurs. In this study, we enrolled inpatients with two
or more of the SIRS symptoms mentioned above within 24
h after ICU admission. Based on results from an etiological
exam and three experienced doctors’ opinions, patients
were divided into a SIRS group and a sepsis group. The
sepsis group was also sub-divided into a sepsis group and a
severe sepsis group (subjects with severe sepsis and septic
shock), according to the severity of conditions. In addition,
with 28-day survival as the cut-off, the patients were also
grouped into survivors, subjects who stayed alive for 28
days (≥ 28 days), and non-survivors who died (< 28 days).
Exclusion criteria were as follows: (1) those under 18
years of age; (2) those who had suffered from anuria for a
long time; (3) those with acquired immunodeficiency syn-
drome; (4) those who had reduced polymorphonuclear
granulocytes (count <500μL-1); (5) those who were receiv-
ing dialysis treatment for chronic kidney disease; and (6)
those who died within 24 h after being taken into the ICU,
refused to become involved in the study, or gave up treat-
ment during the period of observation.
Renal function assessment and diagnosis of AKI
Plasma creatinine concentrations of patients were
detected within 24 hours of being admitted to the ICU for
baseline values [13,14]. Based on the 2006 Acute Kidney
Injury Network (AKIN) definition, AKI involves different
degrees of abnormal kidney structure and function, as well
as signs of abnormal kidney damage lasting no more than
3 months, denoted clinically by blood, urine and tissue
tests, and imaging studies. AKI includes acute renal fail-
ure, acute tubular necrosis, delayed graft function, is char-
acterized by a 48-h increase in serum creatinine levels to
≥25.4 μmol/l (0.3 mg/dl), a percentage increase in serum
creatinine levels of greater than 50%, or a 6-h (or longer)
urine output below 0.5 mlkg-1h-1 [15].
Clinical data collection
Upon admission to the ICU, the following items were
recorded for each patient: age, sex, chief complaints,
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Health Evaluation II (APACHE II) scores, Sequential
Organ Failure Assessment (SOFA) scores, white blood
cells counts (WBC), C-reactive protein (CRP), Procalcitonin
(PCT) urine sCD163 levels, serum creatinine levels, blood
urea nitrogen levels, urine output, mechanical ventilation,
continuous hemodiafiltration, AKI, pathogens, underlying
diseases, and time of admission. A record was also kept of
the 28-day survival rate. Within 24 h after admission, intra-
venous blood was sampled, and urine was collected by a
Folly catheter. Blood was centrifuged at 3000 rpm for 15
minutes, and the urine was centrifuged at 2000 rpm for 5
minutes. Supernatant (2 ml) from both was then transferred
to a 1.5 mL micro-centrifugal tube and stored at -80°C.
ELISA assays
Measurements of sCD163 concentration were obtained by
double antibody sandwich ELISA (a soluble CD163 ELISA
assay for the measurement of macrophage and monocyte
activation, IQ Products, The Netherlands, product num-
ber: IPQ-383). Throughout the experiment, all the urine
samples were diluted by 10 times before concentrations
were measured. In this study, duplicate wells were used to
detect urine sCD163 concentrations. Intra-assay variability
was 3-6% and inter-assay variability was 5-8%. The mini-
mum detectable concentration for the sCD163 assay was
0.23 ng/mL. Each step of examination was carried out in
strict accordance with the product manual.
Statistical analysis
Statistical analysis was performed with SPSS 16.0 (SPSS,
Chicago, IL, USA). Quantitative data with normal distribu-
tions are denoted as mean± standard deviation (SD). The
Student’s t-test was performed to compare means between
two groups. Quantitative data that were abnormally dis-
tributed were denoted as medians (25th and 75th percen-
tiles) and the rank-sum test was conducted. Data of
unordered categories were denoted by rate, and disparities
between two groups were examined using a chi-square
test. A receiver-operating characteristic (ROC) curve was
employed to assess the diagnostic value of sCD163 levels
in patients’ urine for sepsis, as well as sepsis-related AKI
and its prognosis. The "optimal cut-off point" was the
sCD163 concentration at the point on the ROC curve
closest to (0, 1); i.e., to a 1-specificity of 0 and a sensitivity
of 1. The related Pearson coefficient was used to prove the
correlation between serum sCD163 and urine sCD163
concentrations.
Results
Characteristics of the patients
Eighty cases were included in the study, with 20 in the
normal control group, 20 in the SIRS group, and 40 in the
sepsis group. On the basis of 28-day survival, the sepsispatients were further divided into two sub-groups: survi-
vors (20 cases) and non-survivors (20 cases). Table 1 shows
the general condition of the subjects within 24 h after
admission. We found that males were significantly more
likely to contract sepsis than females (P<0.05). Sepsis
patients had significantly higher CRP and serum sCD163
levels, as well as APACHE II scores, than the SIRS patients
(P<0.05). Among the sepsis patients, the survivors had sig-
nificantly higher serum sCD163 and blood urea nitrogen
levels, as well as higher APACHE II and SOFA scores, com-
pared with those of the non-survivors (P<0.05). There
were no differences in age, temperature upon admission,
WBC, PCT, urine output, CCR, serum creatinine, ventilator
use rate, pathogens, etiological examination results, and
past medical history, either between the SIRS and the sepsis
group, or between the survivors and the non-survivors.
Urinary sCD163 concentrations for the diagnosis of sepsis
Urine sCD163 concentrations were not observed in the
20 people in the control group, meaning that they were
below the limit of detection. First-day urine sCD163
concentrations were significantly higher in the SIRS
group (20 cases) (74.8 ng/ml; range: 47.9-148.3 ng/ml)
compared with those in the sepsis group (40 cases)
(31.9; 16.8-48.0 ng/ml, P< 0.001) (Figure 1A). The area
under the receiver-operating characteristic curve (AUC),
which differentiated sepsis from SIRS, was 0.83 (95%
confidence interval [CI]: 0.72-0.94, P< 0.001). With 43.0
ng/ml as the cut-off point, the sensitivity of urine
sCD163 levels for the diagnosis of sepsis was 82.5% and
specificity was 75% (Figure 1B). The sepsis patients were
further divided into a sepsis group (17 cases) and a severe
sepsis group (23 cases). Although the severe sepsis group
appeared to have higher urine sCD163 levels than those in
the sepsis group (76.2; 47.2-167.5 ng/ml vs. 74.2; 46.2-131.6
ng/ml), there was no significant difference between the two
groups (P=0.481, Figure 1C) .
Urine sCD163 levels for the diagnosis of AKI
Fifteen out of the 40 sepsis patients developed AKI in
the course of treatment. We compared urine sCD163
levels of these 15 patients with AKI with the remaining
35 patients upon ICU admission. Urine sCD163 levels in
the AKI group were significantly higher compared with
those in the non-AKI group (121.0; 74.6-299.1 ng/ml vs.
61.8; 42.8-128.3 ng/ml, P= 0.049) (Figure 2A). The AUC,
which differentiated AKI from non-AKI, was 0.69 (95%
CI: 0.51-0.87, P= 0.049). With 73.2 ng/ml as the cut-off
point, the sensitivity of sCD163 levels for AKI diagnosis
was 80% and specificity was 56% (Figure 2B).
Urine sCD163 levels for prognostic assessment
Upon admission, in the sepsis group, we found that
urine sCD163 levels in the non-survivors were higher
Table 1 Clinical and biological data at admission in the intensive care unit
Characteristics SIRS Sepsis
n = 20 Total n = 40 Survivors n = 20 Non-survivors n = 20
Age (years) 55.4 ± 21.4 56.2 ± 19.8 52.7 ± 21.5 59.8 ± 17.8
Gender (n, %)
Male 7 (35) 28 (70) 16 (80) 8 (40)
Female 13 (65) 12 (30)* 4 (20) 12 (60)
temperature (°C) 37.31 ± 0.6 37.70 ± 1.1 37.97 ± 0.9 37.43 ± 1.1
WBC counts (×10∧9/L) 11.7 (9.3-13.0) 10.5 (7.7-17.0) 10.1 (7.7-12.6) 12.6 (7.4-21.9)
serum CRP (mg/dl) 3.4 (1.7-6.0) 11.6 (4.3-17.1)* 8.4 (3.1-15.5) 13.1 (6.1-18.2)
serum PCT (ng/ml) 0.3 (0.2-1.4) 1.9 (0.4-7.4) 1.9 (0.2-7.9) 2.0 (0.6-7.9)
serum sCD163 (ng/ml) 0.3 (0.2-0.4) 2.9 (1.6-11.3)* 1.7 (1.1-4.5) 10.2 (2.7-18.2)#
Renal characteristics
Urinary output (ml/Kg/hr) - 1.5 (1.1-1.9) 1.5 (1.0-1.9) 1.5 (1.1-2.1)
CCr(ml/min) - 90.1 (38.5-120.3) 94.3 (65.7-141.5) 53.1 (31.2-107.0)
SCr(μmmol/L) - 68.0 (55.8-130.7) 63.1 (53.6-96.6) 79.5 (62.1-110.1)
BUN(mmol/L) - 9.2 (6.5-15.6) 7.7 (5.9-10.3) 11.5 (8.9-29.9)#
APACHEII score 11.8 ± 6.7 16.6 ± 7.3* 12.3 ± 6.4 20.9 ± 5.5#
SOFA score - 7.9 ± 4.0 6.1 ± 2.9 9.6 ± 4.2#
MV (n, %) 13 (65) 31 (77.5) 14 (70) 17 (85)
CRRT (n, %) 1 (5) 12 (30)* 4 (20) 8 (40)
Etiological factors (n, %)
Pulmonary infection - 35 (87.5) 18 (90) 17 (85)
Abdominal infection - 9 (22.5) 6 (30) 3 (15)
Urinary tract infection - 11 (27.5) 8 (40) 3 (15)
Trauma/postoperative infection - 16 (40) 10 (50) 6 (30)
Bacteremia - 13 (32.5) 8 (40) 5 (25)
Catheter-related infections - 8 (20) 5 (25) 3 (15)
Others - 1 (2.5) 1 (5) 0 (0)
Pathogens (n, %)
Gram-positive bacteria - 11 (55) 8 (40)
Gram-negative bacteria - 18 (90) 15 (75)
Fungi - 11 (55) 11 (55)
underlying diseases (n, %)
Hypertension 6 (30) 12 (30) 6 (30) 6 (30)
Diabetes 2 (10) 7 (17.5) 3 (15) 4 (20)
COPD 0 (0) 3 (7.5) 3 (15) 0 (0)
Coronary heart disease 3 (15) 4 (10) 2 (10) 2 (10)
Immunosuppressed 0 (0) 7 17.5) 2 (10) 5 (25)
Nervous system disease 0 (0) 3 (7.5) 2 (10) 1 (5)
CKD 1 (5) 7 (17.5) 3 (15) 2 (10)
Quantitative data of normal distribution are presented as mean ± SD. Quantitative data of non-normal distribution are presented as median (25th and 75th
percentiles). Qualitative data are presented as n (%).
APACHE score, Acute Physiologic Assessment and Chronic Health Evaluation II scores; SOFA score, Sequential Organ Failure Assessment scores; MV, mechanical
ventilation; CRRT, continuous renal replacement therapy; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease.
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Figure 1 Urine sCD163 levels on the day of admission to the ICU. A, SIRS group compared with the sepsis group. B, Receiver-operating
characteristic (ROC) curves for urine sCD63 levels for diagnosing sepsis. C, SIRS group compared with the severe sepsis group according to
severity of sepsis. The boxes indicate the interquartile range (IQR). The dark lines denotes the median. The whiskers portray minimum and
maximum values.
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68.0; 44.8-114.5 ng/ml), but this difference was not
significant (P= 0.152, Figure 3A). The AUC, which
differentiated non-survivors from survivors, was 0.63
(95% CI: 0.46-0.81, P= 0.152) (Figure 3B). To more
precisely determine the value of urine sCD163 levels for
prognostic assessment, the AKI patients were further
grouped into survivors (4 cases) and non-survivors (11
cases). Non-survivors appeared to have higher sCD163
levels than survivors (205.9; 38.6-766.0 ng/ml vs. 80.9;
74.9-141.0 ng/ml), but this was not significant (P= 0.361,
Figure 3C).
Correlation between serum sCD163 and urine sCD163
levels
We correlated serum sCD163 and urine sCD163
levels from the 60 patients. A fairly good correlation
was discovered between serum sCD163 and urine
sCD163 levels, with a coefficient of 0.511 (P < 0.001,
(Figure 4).Figure 2 Diagnostic value of urine sCD163 levels for acute kidney inju
operating characteristic (ROC) curves for urine sCD63 levels for diagnosing
denote the median. The whiskers portray minimum and maximum values.Discussion
Sepsis is a common syndrome in critically ill people and
is the leading precipitant of AKI [16], with mortality
rates in excess of 70% [17,18]. Because of the importance
of septic AKI, researchers have found many biomarkers
for this syndrome, such as low-molecular-weight
proteins (β2-microglobulin, α1-microglobulin, adenosine
deaminase binding protein, retinol binding protein,
cystatin C, and renal tubular epithelial antigen-1),
enzymes (N-acetyl-β-glucosaminidase, alanine amino-
peptidase, alkaline phosphatase; lactate dehydrogenase,
α/π-glutathione-S-transferase, and γ-glutamyl transpep-
tidase), cytokines (platelet activating factor and IL-18),
and other biomarkers (kidney injury molecule-1 and Na/
H exchanger isoform-3) [19]. However, early diagnosis of
AKI, especially septic AKI, is still a problem encountered
by clinicians. Inflammation has an important role in the
initiation of and the extension phases of AKI [20].
Therefore, biomarkers for inflammation and the mech-
anism of AKI have attracted much attention.ry (AKI). A, AKI group compared with the non-AKI group. B, Receiver-
AKI. The boxes indicate the interquartile range (IQR). The dark lines
Figure 3 The difference in urine sCD163 levels between survivors and non-survivors based on 28-day survival. A, Patients with sepsis
were divided into groups: the survivors group and non-survivors group. B, Receiver-operating characteristic (ROC) curves for urine sCD63 levels
for the prognosis of sepsis. C, Patients with AKI were divided into groups: the survivors group and non-survivors group. The boxes indicate the
interquartile range (IQR). The dark lines denote the median. The whiskers portray minimum and maximum values.
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currence of sepsis [6,21]. Pathological factors, such as
hemolysis, disseminated intravascular coagulation, and
ischemia reperfusion, as well as toxicity and side effects
from drugs, result in release of hemoglobin/heme, yield-
ing ferrous ions. At the same time, an oxidation reduc-
tion reaction catalyzing hydrogen peroxide leads to
release of oxygen free radicals, causing damage to the
kidney and other organs [22]. Therefore, it is necessary
to clear hemoglobin/heme in a timely manner, prevent-
ing its excessive discharge into the blood and the out-
break of severe pathological responses. Haptoglobin
takes part in the clearance of hemoglobin/heme and is
involved anti-inflammatory metabolism, thus acting as a
brake on relevant toxicity, and warding off oxidativeFigure 4 Correlation between urine sCD163 and serum sCD163 levelsdamage. By means of quantitative urine mass spectrum
analysis (unpublished data), we previously observed an
increase of haptoglobin in the urine of patients with a
poor prognosis. Vanhoutte et al [23] discovered a similar
phenomenon while investigating AKI patients’ urine
through a mass spectrum study (SELDI-TOF-MS).
These findings suggest that hemoglobin/heme clearance
occurs in parts of the kidney under pathological condi-
tions. CD163 is the sole receptor mediating the clear-
ance of hemoglobin/heme [24]. Hemoglobin/heme can
only be cleared by phagocytes when combined with
haptoglobin and through the medium of CD163 [25].
Soluble CD163 is a soluble form of CD163, and its ex-
pression is related to more than one disease [8,26-28].
Especially in recent years, reports have described a high.
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diseases [9]. The scavenger receptor sCD163-Hb partici-
pates in the conversion and clearance of hemoglobin/
heme in the course of chronic diseases [10]. For this rea-
son, we speculate that urine sCD163 is likely to be
highly expressed and reflects kidney injury and develop-
ment of sepsis. However, there are no reports regarding
this issue.
Despite the fact that a normal amount of hemoglobin/
heme can be cleared locally in the kidney, our study
failed to detect sCD163 in the urine from the control
group, which suggests that the technique applied may
not be sensitive enough to measure minute quantities of
sCD163. However, this technique is still effective in the
diagnosis of sepsis. In the current study, urine CD163
concentrations were abnormally increased during sepsis,
with urine sCD163 concentrations in the sepsis group
significantly higher than those in the SIRS group. Urine
sCD163 concentrations also had an ideal sensitivity and
specificity for the diagnosis of sepsis. With regard to
assessment of severity of sepsis by urine sCD163 con-
centrations, despite the finding that urine sCD163 con-
centrations in the severe sepsis group appeared to be
higher than those in the sepsis group, this difference was
not significant. In addition, patients with a poor progno-
sis tended to exhibit higher urine sCD163 concentra-
tions at an early stage, which is helpful for prognosis
assessment. The non-survivors had higher urine sCD163
concentrations than the survivors. As sepsis progresses,
delayed or ineffective treatment will finally lead to AKI.
This explains the higher urine sCD163 concentrations in
AKI patients compared with those in non-AKI patients.
ROC efficiency analysis demonstrated good diagnostic
value of urine sCD163 for AKI because AKI patients had
significantly higher urine sCD163 concentrations than
non-AKI patients. The AUC was 0.69, and the sensitivity
and specificity were 80% and 56%, respectively. Based on
the prognosis after 28 days, we grouped the AKI patients
(15 cases in total) further, finding that after contracting
AKI, the non-survivors had higher sCD163 levels than
the survivors. Because high levels of urine sCD163 often
suggest kidney injury and a bad prognosis, urine sCD163
could be employed to assess the prognosis in patients
who develop AKI. In the present study, we found a mod-
erate correlation between serum and urine sCD163
levels, rendering it possible to make a diagnosis of sepsis
and monitor its development using urine sCD163 levels.
In summary, the detection of sCD163 concentrations in
sepsis and AKI patients leads us to hypothesize that
urine sCD163 levels indicate renal function, they can be
used to differentiate sepsis, and they are useful for the
assessment of prognosis.
Sepsis may be complicated by renal dysfunction [29].
Ischemia and nephrotoxicity injury may interfere withhemoglobin/heme and protein complexes inside renal
cells, leading to an increase of intercellular hemoglobin/
heme [30,31]. In addition, hemoglobin/heme is produced
by sepsis through the megalin/cubilin receptor [32]. It
has been reported that saturation of albumin and/or
damage of megalin/cubulin receptors appears to play a
crucial role in the concentrations of several small mole-
cules [33], which may result in higher hemoglobin/heme
concentrations. Accumulation of hemoglobin/heme is
nephrotoxic in two ways. First, hemoglobin/heme,
through its pro-inflammatory role, mediates renal injury.
With the enhancement of hemoglobin/heme levels in
the body, adhesion molecules in the bowel, liver, kidney,
and other organs are up-regulated, accompanied by
leukocytic recruitment and greater vascular permeability
[34-36]. Second, in this respect, cell toxicity exerts a
direct effect. Plasma and membrane lipid composition
are oxygenated by hemoglobin/heme, which causes
protein denaturation, as well as damage to the integrity
of the cytoskeleton. Hemoglobin/heme lowers the activ-
ity of some enzymes but stimulates the destruction of
some cells. Hemoglobin/heme also leads to DNA oxida-
tion and denaturation [37]. Localized hemoglobin/heme
clearance proceeds inside the kidney. It is important to
prevent irreversible damage to the kidney by this
continuous process. Haptoglobin, combined with
hemoglobin/heme, as well as with the scavenger receptor
CD163 on the surface of phagocytes, and by means of
endocytosis, stimulates the clearance of hemoglobin/
heme. At the same time, CD163 molecules on the cell
membrane peel off, forming a detectable sCD163. The
current study found that when sepsis occurred or when
it was complicated with AKI, sCD163 concentrations
were higher than those in SIRS patients, whereas no sign
of sCD163 was found in the urine of normal persons.
Additionally, the CCR value of 15 patients with AKI was
42.3 ± 21.5 ml/min, which showed moderate damage to
glomeruli. Glomerular injury is caused by localized
inflammatory reactions in the kidney and oxidative
stress, as well as by inducing epithelial and endothelial
cell injury, and inducing changes in the glomerular pore
diameter and charge barrier [20,38]. Soluble CD163 has
a molecular mass of approximately 130,000 daltons, and
an electronegative pI of 5.82 is found in the urine after a
massive compromise of the glomerular barrier. This is
also one of the possible mechanisms of increased
sCD163 concentrations in the urine.
Our study is limited by the following. (1) Our sample
size was limited. We found that although the severe sep-
sis group appeared to have higher sCD163 concentra-
tions than the sepsis group and non-survivors also
appeared to have higher sCD163 concentrations than
survivors, this difference was not significant. The reason
for this might be because of the limited sample size and
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The range of the study was limited. Our study focused
on the clearance mechanism for hemoglobin/heme, with
sepsis patients as subjects. Not just sepsis can induce
AKI, with many other factors involved in causing AKI. It
has been reported that septic AKI may be characterized
by a distinct pathophysiology from non-septic AKI based
on experimental and clinical data [39,40]. Therefore, it is
important to determine whether the increase in biomarkers
in AKI is independent of the increase due to sepsis [41].
However, we did not enroll patients with AKI without
sepsis in this study. Further studies need to be conducted
on hemoglobin-haptoglobin metabolism and sCD163 con-
centrations in the case of acute or chronic renal injury by
other causes. (3) The study results may have been affected
by dialysis treatment. Studies have shown that dialysis
treatment gets rid of hemoglobin/heme. This suggests that
sustained dialysis treatment, which some of the patients
received, had an effect on their sCD163 concentrations.
However, because of the fairly small sample size, we failed
to exclude these patients from the study.
Conclusions
This study suggests, for the first time, the potential value
of urine sCD163 levels for identification of sepsis and
diagnosis of AKI, as well as for early assessment of
patients’ prognosis. As a noninvasive detection index,
urine sCD163 levels may have potential clinical value,
although this is yet to be proved by a larger clinical
sample size.
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